DIVISLAB - Divi's Laboratories

Divi's Laboratories

DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com

Stock Price vs Company Growth

2.7%

2.3%

7.9%

20.3%

46.8%

50.7%

28.3%

10y

21.1%

all

23.4%

🤔 How to analyze this graph?

Last Traded Price

₹ 5,547 2.7%

4,370

5,583

Company Overview

Sales

8,185 Cr

Growth: 2.7%

Profit after Tax

1,674 Cr

Growth: 4.6%

Large Cap

1,47,255 Cr

P/E: 88.0x

Industry P/E: 40.7x

Fundamentals

Sales (Cr)	₹ 8,185
Growth	2.7%
EBITDA	28.4%
P/S	18.0x
Dividend	0.8%
P/E	88.0x
Book Value	₹ 527
PEG Ratio	32.2x
ROE	12.2%
P/B	10.5x

Shareholding Pattern

Institutions

Sbi Mutual Fund

4.49 %

Qualified Institutional Buyer

3.57 %

Axis Mutual Fund Trustee Ltd

3.37 %

Government Pension Fund Global

1.29 %

Life Insurance Corporation Of India

1.15 %

Promoters

Nilima Prasad Divi

20.34 %

Divi Satchandra Kiran

20.34 %

Divi Swarna Latha

5.27 %

Divi'S Biotech Private Limited

3.01 %

Murali Krishna Prasad Divi

2.85 %

Others

Increase Decrease No change

Company Profile Detailed

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.

Belongs to (34 Indices) view more

Investors (127)

credit.s...

divi.mad...

iepf

Followers (41)

deepak

jayapras...

nitin2